Substandard and falsified medical products are increasingly prevalent in developing nations. These products pose a significant threat to human health and place a strain on many resources in the medical industry. Included are pharmaceuticals that contain a different amount or identity of the active ingredient. Such a discrepancy may result in ineffective treatment of illness and inflict harm on the patient. Antibiotics are among the most widely reported classes of substandard and falsified drugs. It is important to the well-being of society to address this growing issue. One effort currently employed to identify these pharmaceuticals is reversed-phase high-performance liquid chromatography (RP-HPLC). Initially, this investigation focused on the development of a method using RP-HPLC to quantify the ampicillin and cloxacillin contained in the antibiotic Ampiclox. Strict guidelines, regulations, and quality assurance procedures specified by the United States Pharmacopeia (USP) must be followed during pharmaceutical analyses. The method was tested to ensure that the separation produces parameters that satisfy USP standards. Following validation, the method was used for the analysis of 21 Ampiclox tablets collected in Liberia. These analyses indicate promising application of the method to future analysis of Ampiclox samples.